IMR Press / EJGO / Volume 21 / Issue 6 / pii/2000244

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Phase II study of high-dose paclitaxel in platinum­refractory epithelial ovarian cancer

Show Less
1 Department of Obstetrics and Gynecology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University,Thailand
2 Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkom University, Bangkok, Thailand
Eur. J. Gynaecol. Oncol. 2000, 21(6), 610–612;
Published: 10 December 2000

The purposes of this study were to determine the efficacy of paclitaxel, using a dose of 200 mg/m2 intravenous continuous infusion over 24 hours every three weeks in the treatemcnt of platinum-refractory epithelial ovarian cancer (EOC) and to evaluate the toxici­ties. Eligibility criteria included: histologically proven EOC, platinum resistance, measurable disease, Zubrod performance status grade 0-2, expected survival of >3 months and adequate hematological function. Response was assessed at three-cycle intervals or earlier if required. Twenty-one patients were recruited in this study. The response rate was 52% (2 CR, 9 PR) with a median duration of response of six months. The median progression-free interval was eight months and the median survival was 12 months. Leukopenia was the predominant toxic effect. Eighty-six percent of patients required granulocyte-colony stimulation factor (G-CSF). All patients had alo­pecia grade 3. In conclusion, high-dose paclitaxel is active in platinum-refractory EOC with manageable toxicities.

PaclitaxeL Epithelial ovarian cancer
Back to top